Loading clinical trials...

Study of Daclizumab in Patients With Chronic, Persistent Asthma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of Daclizumab in Patients With Chronic, Persistent Asthma

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288•Facet Biotech

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•History of asthma for 6 or more months
•History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment

Exclusion Criteria

•Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment
•No significant disease other than asthma

Locations (18)

Medical Research Associates

Long Beach, California, United States

Southern California Research

Mission Viejo, California, United States

Institute of Health Care Assessment, Inc.

San Diego, California, United States

Bensch Research Associates

Stockton, California, United States

National Jewish Medical and Research Center

Denver, Colorado, United States

Clinical Reserch Centers of Colorado

Denver, Colorado, United States

Florida Center for Allergy and Asthma Reserch

Miami, Florida, United States

Rx Research

Woodstock, Georgia, United States

ICSL Clinical Studies

Bloomington, Illinois, United States

Asthma and Allergy Center of Chicago, S.C.

River Forest, Illinois, United States

Key Dates

Start Date

September 1, 2001

Primary Completion Date

December 1, 2003

Completion Date

December 1, 2003

Last Updated

March 13, 2012

Enrollment

120

Estimated participants

Conditions

Asthma

Interventions

Daclizumab

DRUG

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

RECRUITING

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Inclusion Criteria

Exclusion Criteria

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma